DMD and Duchenne muscular dystrophy: Among the splicing‐correcting ASOs, US FDA has approved mRNA eteplirsen, golodirsen, viltolarsen, and casimersen [180], which promote exon skipping in the DMD gene, enabling the production of a partially functional dystrophin protein in patients with Duchenne muscular dystrophy.